Founded in 2018,
The platform technology utilizes water vapor energy to ablate targeted cancerous tissue while preserving surrounding structures, potentially minimizing the side effects often experienced with other cancer treatments.
The investment fits with Coloplast’s strategy to pursue organic and inorganic growth opportunities in the Interventional Urology business. Francis Medical in particular and the prostate cancer segment in general align with the Interventional Urology’s strategic direction, bringing innovative solutions to the urology market.
- “We are proud to be supporting life-changing technologies in growing urology segments. As part of our long-term strategy we are exploring multiple areas for investment and growth, and we are excited about providing solutions in Men’s Health segments like prostate cancer,” said
Steve Blum , President of Interventional Urology.
- “There is a large unmet need for patients seeking treatment alternatives with fewer side effects than radiation or a radical prostatectomy. We are working to address that unmet need and are excited to have the support of a leader in urology like
Coloplast to improve the treatment of prostate cancer,” saidMike Kujak , CEO of Francis Medical.
For more information on Francis Medical please refer to www.francismedical.com
About
Danish medical device company
Learn more on www.coloplast.us/about-coloplast
Global press contact
Lina Danstrup, Senior Media Relations Manager
+45 4911 2607
dklina@coloplast.com
Ellen Bjurgert, Vice President, Investor Relations
+45 49 11 33 76
dkebj@coloplast.com
Attachment
Coloplast completes minority investment in Francis Medical
© OMX, source